Literature DB >> 3805274

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells.

J C White, J P Rathmell, R L Capizzi.   

Abstract

The role of membrane transport in the cellular accumulation of 1-beta-D-arabinofuranosylcytosine (ara-C) was studied in freshly isolated human acute leukemia cells. Patient cells had low rates for ara-C transport as compared with human and murine experimental cells and correspondingly low binding capacities for the nucleoside transport inhibitor, nitrobenzylmercaptopurine riboside (NBMPR). At 1 microM ara-C, the rate of net cellular accumulation was close to the membrane transport rate, and NBMPR inhibited transport and accumulation to the same extent. The rate of ara-C accumulation was half maximal at only 3-5 microM, a level much lower than that required for murine cells (67-85 microM). At concentrations below 1 microM the rate of ara-C accumulation was determined primarily by the transport rate, but at higher concentrations above 10 microM, phosphorylation capacity was the principal determinant of the net uptake rate. This difference in the role of transport at high and low ara-C concentrations may explain, in part, the efficacy of high-dose ara-C in patients refractory to standard dose protocols.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3805274      PMCID: PMC424079          DOI: 10.1172/JCI112823

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside.

Authors:  M H Tattersall; K Ganeshaguru; A V Hoffbrand
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

2.  Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside.

Authors:  R L Momparler; G A Fischer
Journal:  J Biol Chem       Date:  1968-08-25       Impact factor: 5.157

3.  Metabolism of 1-beta-D-arabinofuranosylcytosine in leukemia L1210: nucleoside and nucleotide kinases in cell-free extracts.

Authors:  A W Schrecker
Journal:  Cancer Res       Date:  1970-03       Impact factor: 12.701

4.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Authors:  D H Ho; E Frei
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

5.  Deoxycytidine kinase. 3. Kinetics and allosteric regulation of the calf thymus enzyme.

Authors:  D H Ives; J P Durham
Journal:  J Biol Chem       Date:  1970-05-10       Impact factor: 5.157

6.  Studies on drug resistance. II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-beta-D-arabinofuranosylcytosine.

Authors:  D Drahovsky; W Kreis
Journal:  Biochem Pharmacol       Date:  1970-03       Impact factor: 5.858

7.  An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchangers.

Authors:  J X Khym
Journal:  Clin Chem       Date:  1975-08       Impact factor: 8.327

8.  Lithotripsy. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

9.  Mediated transport of nucleosides in human erythrocytes. Specific binding of the inhibitor nitrobenzylthioinosine to nucleoside transport sites in the erythrocyte membrane.

Authors:  C E Cass; L A Gaudette; A R Paterson
Journal:  Biochim Biophys Acta       Date:  1974-04-12

10.  Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1-beta-D-arabinofuranosylcytosine (Cytarabine).

Authors:  M K Bach
Journal:  Cancer Res       Date:  1969-05       Impact factor: 12.701

View more
  21 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.

Authors:  L M Wang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.

Authors:  B Chandrasekaran; T E Kute; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

5.  Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy.

Authors:  Yuan Zhang; William Y Kim; Leaf Huang
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

6.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

9.  Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.

Authors:  Daniel Shepshelovich; Yonatan Edel; Hadar Goldvaser; Tal Dujovny; Ofir Wolach; Pia Raanani
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

10.  Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  R A Fleming; R L Capizzi; G L Rosner; L K Oliver; S J Smith; C A Schiffer; R T Silver; B A Peterson; R B Weiss; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.